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Fusion proteins created by chromosomal abnormalities
are key components of mesenchymal cancer development.
The most common chromosomal translocation in liposar-
comas, t(12;16)(q13;p11), creates the FUS –CHOP
fusion gene. In the past, we generated FUS –CHOP
and CHOP transgenic mice and have shown that while
FUS –CHOP transgenic develop liposarcomas, mice
expressing CHOP, which lacks the FUS domain, display
essentially normal white adipose tissue (WAT) develop-
ment, suggesting that the FUS domain of FUS –CHOP
plays a specific and critical role in the pathogenesis of
liposarcoma. To test the significance of FUS and CHOP
domain interactions within a living mouse, we generated
mice expressing the FUS domain and crossed them with
CHOP-transgenic mice to generate double-transgenic
FUSxCHOP animals. Here we report that expression
of the FUS domain restores liposarcoma development in
CHOP-transgenic mice. Our results provide genetic
evidence that FUS and CHOP domains function in trans
for the mutual restoration of liposarcoma. These results
identify a new mechanism of tumor-associated fusion
genes and might have impact beyond myxoid liposarcoma.
Oncogene (2002) 21, 1679 – 1684. DOI: 10.1038/sj/
onc/1205220
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Introduction
Liposarcoma is the most common soft tissue malig-
nancy in adults accounting for at least 20% of all
sarcomas in this age group (Chang et al., 1989; Mack,
1995). The myxoid/round cell liposarcomas exhibited
the characteristic t(12;16)(q13;p11) translocation
(Knight et al., 1995). The molecular characterization
of this translocation revealed a fusion between the
CHOP gene and a gene called TLS/FUS (Crozat et al.,
1993; Rabbitts et al., 1993), resulting in the RNA-
binding domain of TLS/FUS being replaced by the
basic leucine zipper domain of CHOP, which confers
the ability to form protein dimers (Ron and Habener,
1992; Crozat et al., 1993). The TLS/FUS gene has also
been shown to fuse with the gene for Ets-like protein
ERG as a result of the translocation t(16;21)(p11;q22)
in some patients with acute nonlymphoblastic leukemia
(Shimizu et al., 1993; Ichikawa et al., 1994; Panago-
poulos et al., 1994, 1995). The portion of TLS/FUS
that is present in the TLS/FUS –CHOP and FUS–
ERG fusion proteins is similar and this part has been
shown to be an autonomous transcriptional activation
domain (Prasad et al., 1994; Sa´nchez-Garcı´a and
Rabbitts, 1994; Zinszner et al., 1994). In the FUS–
CHOP fusion, transcriptional activation is therefore
specifically conferred on the chimeric protein by the
FUS segment after the translocation event (Sa´nchez-
Garcı´a and Rabbitts, 1994). In vitro, the transforming
eects of FUS –CHOP have been demonstrated in
fibroblasts (Pe´rez-Losada et al., 2000a), but curiously
not in 3T3 –L1 cells under conditions expected to yield
oncogenic eects (Zinszner et al., 1994), suggesting that
the function of FUS –CHOP is influenced by the cell
environment in vitro. In vivo, mice expressing FUS–
CHOP develop liposarcomas (Pe´rez-Losada et al.,
2000a). Whereas interference with the normal process
of dierentiation may contribute to the oncogenic
potential of FUS –CHOP fusion protein, it is a
property that they share with the nontransforming
germline CHOP gene product (Zinszner et al., 1994;
Batchvarova et al., 1995). CHOP expression is tightly
regulated. Under normal conditions the gene is
repressed, and CHOP mRNA and protein are absent
from cells (Fornace et al., 1989; Price and Calderwood,
1992; Carlson et al., 1993; Wang et al., 1996). In
contrast with CHOP, FUS is a constitutively activated
gene (Aman et al., 1996). These observations support a
model whereby the FUS–CHOP fusion gene repre-
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sents a gain-of-function mutation of CHOP that
deregulate both gene expression and protein activity.
However, mice expressing high levels of CHOP, which
lacks the FUS domain, display normal white adipose
tissue (WAT) development (Pe´rez-Losada et al.,
2000b), suggesting that the FUS component of the
fusion protein acts an autonomous domain which plays
a specific and critical role in the pathogenesis of
liposarcoma. To test the significance of FUS and
CHOP domain interactions within a living mouse, we
generated mice expressing the FUS domain and
crossed them with CHOP-transgenic mice to generate
double-transgenic FUSxCHOP animals. Here we
report that expression of the FUS domain restores
liposarcoma development in CHOP-transgenic mice.
Our results provide genetic evidence that FUS and
CHOP domains function in trans for the mutual
restoration of liposarcoma and support a model
whereby the FUS–CHOP fusion gene represents a
gain-of-function mutation of both FUS and CHOP.
This novel molecular mechanism may be responsible
for the development of these and other related solid
tumors.
Results
Generation of transgenic mice expressing an altered form
of FUS –CHOP protein lacking the CHOP domain
We previously developed a mouse model of liposarco-
ma by expressing FUS–CHOP from the elongation
factor 1a (EF-1a) promoter in murine mesenchymal
stem cells (Pe´rez-Losada et al., 2000b). In order to
understand in vivo the role of FUS –CHOP in the
pathogenesis of liposarcoma, we have also generated
transgenic mice expressing two altered forms of the
FUS–CHOP protein (Pe´rez-Losada et al., 2000a). The
first truncated protein (CHOP) which lacks the FUS
domain did not aect WAT development in vivo. The
second altered form of FUS–CHOP, created by the in
frame fusion of the FUS domain to the carboxy end of
CHOP (CHOP–FUS), induced liposarcomas in trans-
genic mice indicating that the FUS domain of FUS –
CHOP plays a specific and critical role in the
pathogenesis of liposarcoma (Pe´rez-Losada et al.,
2000b). To test the significance of FUS and CHOP
domain interactions within a living mouse, we have
now generated mice expressing the FUS domain, a
truncated FUS–CHOP protein lacking the CHOP
domain, to investigate the contribution of the FUS
domain to the genesis of liposarcoma in vivo (Figure
1a). In vitro this truncated protein (FUS) is able to
activate transcription (Prasad et al., 1994; Sa´nchez-
Garcı´a and Rabbitts, 1994; Zinszner et al., 1994).
In order to examine the direct consequences of FUS
expression in vivo we follow the same strategy than we
previously used for FUS –CHOP (Pe´rez-Losada et al.,
2000a). Therefore, FUS cDNA was cloned downstream
from the EF-1a promoter (EF –FUS) to direct expres-
sion to all tissues (Figure 1b) and injected into C57BL/
6xCBA fertilized eggs. Tissue expression of the EF –
FUS transgene was demonstrated by Western blot
analysis with an 9E10 monoclonal antibody (Figure 1c).
WAT development is normal in EF-FUS transgenic mice
Cohorts of transgenic mice were generated to analyse
the eect of the FUS gene. FUS transgenic mice
developed healthy, were fertile and none of the FUS
transgenic mice developed liposarcomas in up to 24
months of observation. This result is similar to CHOP
transgenic mice (Pe´rez-Losada et al., 2000b) and
contrasts with our observations in the FUS –CHOP
transgenic mice which develop liposarcomas (Pe´rez-
Losada et al., 2000a). Although liposarcomas did not
develop in the FUS transgenic mice, we investigated
whether the FUS protein altered white adipose tissue
(WAT) development in these mice. The histopatholo-
gical analyses of the white adipose depots in FUS
transgenic mice did not evidence any pathological
change within the terminally dierentiated adipocytes
(Figure 2). On the contrary, FUS transgenic mice had
a normal architecture of the tissue and we did not
observe any shift in the WAT toward immature in the
FUS transgenic mice.
Double-transgenic FUSxCHOP mice develop
liposarcomas
We next investigated the significance of FUS and
CHOP domain interactions within a living mouse and
crossed mice expressing the FUS domain with CHOP-
transgenic mice (Pe´rez-Losada et al., 2000b) to
generate double-transgenic FUSxCHOP animals (Fig-
ure 1c). Uniformly, male and female double-transgenic
FUSxCHOP animals showed the same symptoms
beginning as early as 8 – 12 weeks of age with
increasing signs over time leading to death by 12
months of age. At the time of autopsy, these animals
had developed palpable masses involving the adipose
tissues, which, upon dissection, revealed white adipose
pads 4 – 100-fold normal size. All these animals had
visible masses as early as 8 – 10 weeks. In addition,
some animals never developed palpable masses but
showed microscopic tumor upon dissection when they
were sacrified at 12 weeks of age. This examination is
consistent with adipose tissue disease. However, no
tumors of other tissues were found in these double-
transgenic FUSxCHOP animals, despite widespread
activity of the EF-1a promoter. Although we did not
detect the presence of FUS –CHOP protein in our
double-transgenic FUSxCHOP animals (Figure 1c), the
possibility of recombination of FUS and CHOP
resulting in expression of fused FUS –CHOP sequences
in the double-transgenic FUSxCHOP animals was
ruled out by PCR with FUS forward and CHOP
reverse primers (data not shown).
We next defined the adipose tissue disease
generated in the double-transgenic FUSxCHOP
animals. Detailed analysis of the tumor cells estab-
lished the diagnosis as malignant liposarcomas.
Mechanisms by which FUS-CHOP can initiate liposarcoma
PA Pe´rez-Mancera et al
1680
Oncogene
Haematoxilin/Eosin staining showed that the tumor
cells had an adipoblast morphology (Figure 3).
Histologically, all tumors were diuse liposarcomas
composed of medium to large cells with round nuclei
and were very similar to human liposarcomas
(see http://www-medlib.med.utah.edu/WebPath/NEO-
HTML/NEOPLO52.html) and liposarcomas generated
in FUS–CHOP transgenic mice (Pe´rez-Losada et al.,
2000a). Similarly to FUS –CHOP transgenic mice, the
histopathological analyses of the white adipose depots
in the double-transgenic FUSxCHOP animals revealed
multiple abnormalities. Some contained only modest
morphological changes consisting primarily of an
increase in nuclear size and number per microscopic
field, but the white adipose tissue (WAT) of a majority
of the mice had a much more hypercellular appearance
and contained scattered cells with enlarged pleo-
morphic nuclei (Figure 3). Nests of compact anaplastic
liposarcoma cells were often scattered throughout the
WAT depots. Similarly to FUS –CHOP transgenic
mice, WAT deposits in these animals were generally
aected at least with abnormal adipocytes and, in
some cases, foci of sarcomas were clearly discernible.
Pathological changes were not observed in the brown
adipose tissue (BAT) of these transgenic mice. Tumor
infiltration of non-adipose tissues was usually visible
and was confirmed microscopically (Figure 4). These
data define the tumors generated in the double-
transgenic FUSxCHOP as malignant liposarcomas.
We next examined the expression of adipocyte-specific
genes in order to define the level at which the
dierentiation is blocked in FUSxCHOP liposarcomas.
Similarly to FUS–CHOP transgenic mice (Pe´rez-
Losada et al., 2000a) and despite their block in
dierentiation each liposarcoma examined was found
to express significant levels of PPAR-g RNA, c/EBPb,
d and a and aP2 comparable to that of normal fat and
FUS –CHOP liposarcomas (data not shown). These
results suggest that liposarcomas in the double-
transgenic FUSxCHOP mice have been transformed
at a point in the dierentiation process after induction
of PPARg expression. Moreover, PPARg is not
Figure 1 FUS and double FUSxCHOP transgenic mice. (a) Schematic representation of the FUS–CHOP protein created as a
result of the t(12;16)(q13;p11) chromosomal translocation and the altered form of FUS–CHOP, FUS protein, used in this study. (b)
The human FUS cDNA containing a tag-sequence for the human c-Myc (amino acids 408 – 439) at the 3’ end was cloned into the
pEF–BOS vector, which contains the EF-1 promoter sequences and polyadenylation and splice signals from the human G-CSF
gene, to give pEF–FUS. (c) Expression of the pEF–FUS transgene and expression of FUS and CHOP proteins in double
FUSxCHOP transgenic mice was determined by Western blot analysis in the fat of a 2-month-old EF–FUS and double
FUSxCHOP transgenic, respectively. As a negative control we used the fat from a 2-month-old CHOP transgenic littermate. The
location of FUS and CHOP is as indicated
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expressed in any other type of soft tissue sarcoma
(Tontonoz et al., 1997) and can be considered a
sensitive marker for distinguishing liposarcoma from
other histologic types of soft tissue sarcoma. There-
fore, the double-transgenic FUSxCHOP mice repro-
duce the same phenotype with which the FUS –CHOP
fusion gene is associated both in human pathology and
transgenic mice (Pe´rez-Losada et al., 2000a). These
observations provide genetic evidence that FUS and
CHOP domains function in trans for the mutual
restoration of liposarcoma.
Embryonic fibroblasts from FUS mice differentiate into
adipocytes but adipocyte differentiation is blocked in
embryonic fibroblasts from double-transgenic
FUSxCHOP mice
To investigate whether the FUS domain could restore
the same adipocyte inhibition capacity than FUS–
CHOP in CHOP-expressing cells, we prepared primary
embryonic fibroblasts from FUS and double-trans-
genic FUSxCHOP mice and examined their dier-
entiation properties as previously described (Pe´rez-
Losada et al., 2000a). The embryonic fibroblasts from
each line were cultured to confluent and then treated
with the standard dierentiation induction medium.
As shown in Figure 5, embryonic fibroblasts from
FUS and CHOP mice dierentiated into adipocytes
and accumulated many lipid droplets in response to
hormonal stimulants. In contrast, embryonic fibro-
blasts from double-transgenic FUSxCHOP mice can
hardly dierentiate into adipogenic cells and accumu-
late very few lipid droplets, similarly to FUS –CHOP
embryonic fibroblasts (Figure 5). The Oil-Red-O
staining demonstrated clear dierences in adipocyte
phenotype (Figure 5) and, similarly to FUS –CHOP
MEFs, MEFs from double-transgenic FUSxCHOP
mice only expressed the earliest markers of dierentia-
tion (data not shown), which corresponds to pre-
adipocytes. These results show that adipocyte
dierentiation was blocked in cultured embryonic
fibroblasts from double-transgenic FUSxCHOP mice
but not in MEFs derived from CHOP transgenic mice
treated with adipogenic hormons. Interference with
the normal process of dierentiation contributes to the
oncogenic potential of FUS –CHOP fusion protein
(Pe´rez-Losada et al., 2000a) and this capacity is
restored by the FUS domain into CHOP-expressing
cells.
Figure 2 Histologic appearance of the adipose tissues in EF–
FUS transgenic mice. Hematoxylin-eosin stained section of the
adipose tissues coming from wild-type (610) and FUS transgenic
mice (620)
Figure 3 WAT abnormalities in double-transgenic FUSxCHOP
animals. Hematoxylin-eosin stained section of the adipose tissue
in the region of the testis from a double-transgenic FUSxCHOP
mouse shows the eacement of the normal fat architecture
compared to control mice. The presence of the lipoblasts are
visible in this liposarcoma. Although the liposarcoma disease in
FUSxCHOP transgenic mice was very similar to FUS–CHOP
mice, the level of adipoblast infiltration revealed by histological
analysis was not identical. Similar results were found in multiple
sections from double-transgenic FUSxCHOP mice. The original
magnification is 610
Figure 4 Adipocytic infiltration of liver and kidney in double-
transgenic FUSxCHOP mice. Hematoxylin-eosin stained sections
of the liver and kidney tissues coming from wild-type and
FUSxCHOP transgenic mice
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Discussion
We have demonstrated that directing expression of
the FUS–CHOP fusion protein to immature mouse
cells initiated sarcomas with adipose features (Pe´rez-
Losada et al., 2000a). We have similarly expressed
altered forms of FUS –CHOP, showing that the
truncated protein CHOP which lacks the FUS
activation domain does not generate any tumors
neither aect the development of WAT in vivo
(Pe´rez-Losada et al., 2000b). Concordant with these
data, adipocyte dierentiation was not blocked in
cultured CHOP embryonic fibroblasts treated with
adipogenic hormones. Thus, these results show that
the transcriptional activation by FUS is indispensable
for tumorigenesis. However, these results do not
clarify whether the relationship between the FUS
and CHOP domains is in cis or in trans. To test the
significance of FUS and CHOP domain interactions
within a living mouse, we generated mice expressing
the FUS domain and crossed them with CHOP-
transgenic mice to generate double-transgenic FUSx-
CHOP animals. Here we show that expression of the
FUS domain restores liposarcoma development in
CHOP-transgenic mice. Double-transgenic FUSx-
CHOP animals resulted in most of the symptoms of
human liposarcomas, including the presence of
lipoblasts with round nuclei, accumulation of intra-
cellular lipid, induction of adipocyte-specific genes and
a concordant block in the dierentiation program. No
tumors of other tissues were found in these transgenic
mice despite widespread activity of the EF1a
promoter, underscoring the relevance of relationship
between FUS-CHOP and the cell environment
(Sa´nchez-Garcı´a, 1997). Our results provide genetic
evidence that FUS and CHOP domains function in
trans for the mutual restoration of liposarcoma and
support a model whereby the FUS –CHOP fusion
gene represents a gain-of-function mutation of both
FUS and CHOP that deregulate both gene expression
and protein activity. Further studies to identify the
target genes and proteins that are regulated by FUS–
CHOP using our transgenic mice will produce a
clearer picture of the development defect in liposarco-
ma. In conclusion, our results identify a new
molecular mechanism responsible for the genesis of
solid tumor-associated fusion genes which might have
impact beyond myxoid liposarcoma.
Material and methods
The generation and screening of transgenic mice
PCR amplification of the FUS portion of FUS–CHOP was
done to facilitate cloning by adding restriction enzymes using
primers that hybridize to the 5’ and 3’ ends of the FUS
cDNA. The product was cloned into the M13mp19 vector,
added to 3’ end an in-frame sequence coding for a MYC-tag
recognized for the 9E10 antibody, and sequenced. The cDNA
was cloned into a plasmid, pEF–BOS, containing sequences
of the EF1-a promoter, followed by a polylinker region
linked to the poly(A) adenylation signal from human G-CSF
cDNA as described (Mizushima and Nagata, 1990). Linear
DNA fragments for microinjection were obtained by HindIII
digestion and injected by the INIA Transgenic Facility into
CBAxC57BL/6J fertilized eggs. Transgenic founders were
identified by Southern-blot analysis through detection of the
novel EF-FUS construct from samples of DNA extracted
from tails, respectively. CHOP mice has been previously
described (Pe´rez-Losada et al., 2000b) and double-transgenic
FUSxCHOP animals were generated by crossing FUS and
CHOP transgenic mice.
Histological analysis
FUS and double-transgenic FUSxCHOP mice were subjected
to standard necropsy. All major organs were closely
examined under the dissecting microscope, and samples of
each organ were processed into paran, sectioned and
examined histologically. Tumor specimens from the trans-
genic mice were fixed into 10% formalin overnight, then
Figure 5 Adipogenic dierentiation from primary embryonic fibroblasts expressing altered forms of FUS–CHOP protein. Primary
embryonic fibroblasts from each transgenic line were cultured in the presence of standard dierentiation induction medium
(containing 0.5 mM isobutylmethylxantine, 1 mM dexamethasone, 5 mg/ml insulin and 10% FBS). After 8 days of dierentiation,
cells were observed by light microscopy with Oil-Red-O staining. Cells from FUS, CHOP and double-transgenic FUSxCHOP mice
are shown. The original magnification is 620. This experiment was repeated three times using cells prepared from all transgenic
lines and from dierent embryos and similar results were obtained
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processed, embedded in paran, and 6 mm sections were
stained with hematoxylin and eosin and photographed. All
tissue samples were taken from homogenous and viable
portions of the resected sample by the pathologist (T. Fores)
and fix within 2 – 5 min of excision.
Preparation of primary embryonic fibroblasts and induction of
adipogenic differentiation
Primary embryonic fibroblasts were harvested from 14.5
d.p.c. embryos. Cells were cultured at 378C in Dulbecco’s
modified Eagle’s medium (DMEM; Boehringer Ingelheim)
supplemented with 10% heat-inactivated FBS (GIBCO/
BRL). Cells were plated to 24-well or 60 mm plastic dishes
and propagated to confluence. Two days later, medium was
replaced with standard dierentiation induction medium
containing 0.5 mM isobutylmethylxantine (Sigma), 1 mM
dexamethasone (Sigma), 5 mg/ml insulin (Sigma) and 10%
FBS (GIBCO/BRL). This medium was removed every other
day. After 8 days, the appearance of cytoplasmic lipid
accumulation was observed by microscopy with Oil-Red-O
staining. The Oil-Red-O staining was performed as follows:
cells were washed with phosphate-buered saline (PBS), and
then stained with 60% filtered Oil-Red-O stock solution
(0.15 g of Oil-Red-O (Sigma) in 50 ml of isopropanol) for
30 min at 378C. Cells were washed first with 60%
isopropanol and then briefly with water and visualized.
Western blot analysis
Single cell suspensions coming from dierent tissue samples
were analysed by immunoblotting procedures essentially as
described (Castellanos et al., 1997). Lysates were run on a
10% SDS–PAGE gel and transferred to a PVDF membrane.
After blocking, the membrane was probed with c-Myc (9E10)
mouse monoclonal antibody (Santa Cruz), which is specific
for human c-Myc (amino acids 408 – 439). Reactive bands
were detected with an ECL system (Amersham).
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